5-alpha reductase inhibitors for benign prostatic hyperplasia

References

Citations

1. AUA Practice Guidelines Committee (2003). AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. Journal of Urology, 170(2, Part 1): 530–547.

2. Webber R (2005). Benign prostatic hyperplasia. Clinical Evidence (14): 1076–1091.

3. Roehrborn CG, et al. (2002). Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 60(3): 434–441.

4. Nickel JC (2004). Comparison of clinical trials with finasteride and dutasteride. Reviews in Urology, 6(Suppl 9): S31–S39.

5. McConnell JD, et al. (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine, 349(25): 2387–2398.

Author:	Douglas Dana Ralph Poore	Last Updated: August 30, 2006
Medical Review:	Martin Gabica, MD - Family Medicine Adam Husney, MD - Family Medicine J. Curtis Nickel, MD, FRCSC - Urology Christopher G. Wood, MD, FACS - Urology/Oncology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.